Malignant Carcinoid Syndrome

Download PDF

Recent Publications on Malignant Carcinoid Syndrome:
Reversible parkinsonism and ataxia associated with high-dose octreotide. Interventional procedures for oncology patients are being used more...	3rd July, 2008	Department of Neurology, University of Cincinnati, 231 Albert Sabin Way,	Neurology. 2008 Jun 10;70(24):2345-6. Epub 2008 May 7. DOI Direct Link
High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss. Carcinoid tumors of the small intestine are characterized by an indolent...	27th June, 2008	Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA,	Genes Chromosomes Cancer. 2008 Jul;47(7):591-603. DOI Direct Link
Carcinoid syndrome with angioedema and urticaria. Interventional procedures for oncology patients are being used more...	25th June, 2008		Arch Dermatol. 2008 May;144(5):691-2. DOI Direct Link
Carcinoid syndrome. As clinical awareness increases, carcinoid is becoming increasingly...	26th March, 2008	Department of Surgery, University Hospital Aintree, Liverpool L9 7AL, UK.	Eur J Surg Oncol. 2008 Mar;34(3):289-96. Epub 2007 Dec 18. DOI Direct Link
Analysis of 150 patients with carcinoid syndrome seen in a single year at one institution in the first decade of the twenty-first century. Carcinoid heart disease (CHD), reported in 50% to 70% of patients with...	13th March, 2008	Carcinoid Heart Disease Clinic, Department of Cardiology, Royal Free	Am J Cardiol. 2008 Feb 1;101(3):378-81. Epub 2007 Dec 21. DOI Direct Link
→View more research publications.

Malignant Carcinoid Syndrome Clinical Trials:
Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome	Malignant Carcinoid Syndrome
Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery	Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neoplastic Syndrome
Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors	Gastrointestinal Carcinoid Tumor;   Lung Cancer
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors	Gastrointestinal Carcinoid Tumor;   Islet Cell Carcinoma
Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer	Extrahepatic Bile Duct Cancer;   Gastric Cancer;   Gastrointestinal Carcinoid Tumor;   Liver Cancer;   Pancreatic Cancer;   Small Intestine Cancer
→View more trials.

Malignant Carcinoid Syndrome Patents:
US Patent No.	Title
5489508	Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
5837453	Telomerase activity assays
5840495	Methods for diagnosis of conditions associated with elevated levels of telomerase activity
5863726	Telomerase activity assays
5869035	Methods and compositions for inducing complement destruction of tissue
→View more patents.

BioPortfolio Ltd. offers e-mail and postal lists for Malignant Carcinoid Syndrome scientists - we have details of around 156 individuals working on Malignant Carcinoid Syndrome .

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.